Elanco Animal Health (ELAN) Stock Price, News & Analysis

Company Overview

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Key Stats

• Today's Range: $12.01 to $12.28
• 50-Day Range: $8.14 to $12.29
• 52-Week Range: $8.02 to $18.80
• Volume: 4.23 million shs
• Average Volume: 4.98 million shs
• Market Capitalization: $6.03 billion
• P/E Ratio: 30.35
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Elanco Animal Health Stock Analysis - MarketRank™

Elanco Animal Health scored higher than 69% of companies evaluated by MarketBeat, and ranked 320th out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Elanco Animal Health has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Elanco Animal Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -2.20%

Earnings Growth

Earnings for Elanco Animal Health are expected to decrease by -2.20% in the coming year, from $0.91 to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elanco Animal Health is 30.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.25.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elanco Animal Health is 30.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.05.

Price to Earnings Growth Ratio

Elanco Animal Health has a PEG Ratio of 2.50. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Elanco Animal Health has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.45% of the float of Elanco Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Elanco Animal Health has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Elanco Animal Health has recently increased by 33.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elanco Animal Health does not currently pay a dividend.

Dividend Growth

Elanco Animal Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 0.3 / 5
• Environmental Score: -4.69

Percentage of Shares Shorted

4.45% of the float of Elanco Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Elanco Animal Health has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Elanco Animal Health has recently increased by 33.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Elanco Animal Health has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Elanco Animal Health this week, compared to 12 articles on an average week.

Search Interest

11 people have searched for ELAN on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Elanco Animal Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $211,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.89% of the stock of Elanco Animal Health is held by insiders.

Percentage Held by Institutions

97.48% of the stock of Elanco Animal Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELAN Stock Analysis - Frequently Asked Questions

How have ELAN shares performed this year?

Elanco Animal Health's stock was trading at $12.11 at the beginning of the year. Since then, ELAN stock has decreased by 0.1% and is now trading at $12.10.
View the best growth stocks for 2025 here.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) announced its quarterly earnings results on Wednesday, May, 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year.
Read the conference call transcript.

When did Elanco Animal Health IPO?

Elanco Animal Health (ELAN) raised $1.4 billion in an initial public offering on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Top institutional shareholders of Elanco Animal Health include Douglas Lane & Associates LLC (0.78%), Private Management Group Inc. (0.53%), Federated Hermes Inc. (0.44%) and Bank of New York Mellon Corp (0.39%). Insiders that own company stock include R David Hoover, Jeffrey N Simmons, Lawrence Erik Kurzius, Michael J Harrington, John P Bilbrey and Rajeev A Modi.
View institutional ownership trends.

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elanco Animal Health investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), Pfizer (PFE), Bank of America (BAC), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ELAN
• CIK: 1739104
• Web: www.elanco.com
• Phone: (877) 352-6261
• Fax: N/A
• Employees: 9,800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $19.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +22.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.74
• Trailing P/E Ratio: 30.71
• Forward P/E Ratio: 13.50
• P/E Growth: 2.5
• Net Income: $-1,231,000,000.00
• Net Margins: 4.60%
• Pretax Margin: 9.25%
• Return on Equity: 6.78%
• Return on Assets: 3.03%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 2.55
• Quick Ratio: 1.31

Sales & Book Value

• Annual Sales: $4.43 billion
• Price / Sales: 1.38
• Cash Flow: $2.54 per share
• Price / Cash Flow: 4.84
• Book Value: $12.63 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 496,458,000
• Free Float: 491,535,000
• Market Cap: $6.10 billion
• Optionable: Optionable
• Beta: 1.49